Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565869 | 0.85 | EPHX1 (0.46) | EPHX1EPHX2HSD11B1 | |
| SCHEMBL1565658 | 0.80 | KDM4E (0.42) | EPHX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1566490 | 0.79 | EPHX1 (0.51) | EPHX1FFAR1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1565099 | 0.78 | CTSA (0.43) | — | |
| SCHEMBL1564996 | 0.77 | LMNA (0.44) | EPHX1SLC6A2 | |
| SCHEMBL1565612 | 0.77 | MEN1 (0.42) | EPHX1EPHX2SLC6A2 | |
| SCHEMBL11304688 | 0.75 | LMNA (0.42) | EPHX1 | |
| SCHEMBL761250 | 0.74 | TRPM8 (0.46) | FFAR1NOTUMEPHX2TRPM8GPR139 | |
| SCHEMBL1275951 | 0.74 | CTSA (0.47) | FFAR1NOTUMEPHX2TRPM8GPR139 | |
| SCHEMBL1565332 | 0.74 | SRD5A2 (0.43) | EPHX1FFAR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | EPHX1 2427/4885FFAR1 205/4885TAS1R3 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.